Metrics to compare | TRNG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRNGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −3.1x | −0.4x | |
PEG Ratio | −0.53 | −0.06 | 0.00 | |
Price/Book | 1.7x | 1.7x | 2.6x | |
Price / LTM Sales | 29.2x | 11.2x | 3.1x | |
Upside (Analyst Target) | 41.9% | 169.5% | 48.3% | |
Fair Value Upside | Unlock | 2.5% | 6.1% | Unlock |
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.